Europe API Intermediates Market - Industry Trends and Forecast to 2030

Europe API Intermediates Market, By Type (Veterinary Drug Intermediates Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others) - Industry Trends and Forecast to 2030.

Europe API Intermediates Market Analysis and Size

Pharmaceutical companies are actively involved in research and development (R&D) to create new drugs and improve existing formulations. This R&D effort requires a steady supply of high-quality API intermediates. Many pharmaceutical companies in Europe are outsourcing the production of API intermediates to third-party manufacturers, including those in other regions like Asia. This outsourcing allows European companies to reduce production costs and focus on drug development and marketing. The development of biosimilar, which are biological drugs that are highly similar to existing biologic products, has been on the rise in Europe. Producing biosimilar requires a reliable supply of API intermediates, contributing to market growth.

Data Bridge Market Research analyses that the Europe API intermediates market which was USD 49,400.00 million in 2022, is expected to reach USD 79,332.30 million by 2030, and is expected to undergo a CAGR of 6.1% during the forecast period 2023-2030. This indicates the market value. “Veterinary Drug Intermediates Pharmaceutical” dominates the type segment of the Europe API intermediates market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Europe API Intermediates Market Scope and Segmentation

Market Definition

The active pharmaceutical ingredient (API) intermediates are the chemical compounds that are used as intermediate products in the synthesis or manufacturing of active pharmaceutical ingredients (APIs). API intermediates are essential components in the pharmaceutical manufacturing process, as they serve as building blocks for the creation of the final API. API intermediates are chemical compounds that are synthesized during the production of active pharmaceutical ingredients (APIs). They are intermediate stages in the chemical synthesis pathway, and they undergo further processing and modifications to ultimately become the API of a pharmaceutical product. API intermediates are crucial in the pharmaceutical industry, as they play a vital role in determining the quality, purity, and efficacy of the final drug product.

Europe API Intermediates Market Dynamics

Drivers

• Pharmaceutical Industry Growth

The pharmaceutical industry in Europe is characterized by a robust pipeline of new drug candidates and therapies. As pharmaceutical companies invest in research and development (R&D) to bring innovative drugs to market, they require a steady supply of high-quality API intermediates. Each new drug development project necessitates specific intermediates tailored to the drug's molecular structure. Pharmaceutical companies in Europe are engaged in the development of drugs across a wide range of therapeutic areas, including oncology, cardiovascular diseases, neurology, infectious diseases, and rare diseases. The diversity of therapeutic areas leads to a variety of API intermediate requirements, stimulating demand in the market.

• Rising Research and Development

Ongoing research and development efforts in the pharmaceutical sector lead to the creation of new drugs and therapies, requiring specific API intermediates. Pharmaceutical companies in Europe continually invest in R&D to discover and develop new drugs and therapies. The early stages of drug discovery and development often involve the synthesis and testing of numerous compounds, including API intermediates. As more drug candidates enter development pipelines, the demand for specialized intermediates increases. R&D efforts often focus on the development of customized drug formulations tailored to specific patient populations or therapeutic needs. This customization requires the synthesis of unique API intermediates that match the desired molecular structures and characteristics of the APIs.

Opportunity

• Rising Research Collaborations

Collaborations between pharmaceutical companies and research institutions in Europe often lead to the development of novel drugs and therapies. These research efforts may require the synthesis of specific API intermediates. The growth of the pharmaceutical industry in Europe is intricately linked to the demand for API intermediates. The development of new drugs, adherence to regulatory standards, customization needs, outsourcing practices, and expansion into emerging markets all contribute to the increasing demand for high-quality and reliable API intermediates in Europe.

Restraint/Challenge

• Regulatory Hurdles

The pharmaceutical industry, including the API intermediates sector, is subject to strict regulatory oversight in Europe. Compliance with Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and other quality and safety standards is mandatory. Meeting these stringent requirements can be costly and time-consuming. Europe places a strong emphasis on environmental protection. API intermediate manufacturing processes often involve the use of chemicals and solvents. Compliance with environmental regulations, waste management, and sustainable practices can be challenging and expensive.

Recent Developments

• In January 2021, Vertellus has been acquired by the company, Pritzker Private Capital who partners with the middle-market companies established in North America and builds up the long-term relationship with that company. As Vertellus is considered as leading company or provider of specialty chemicals in different sectors such as healthcare, food & agriculture, personal care, transportation and coatings, so PPC has made a partnership with the company. This helped the company Vertellus to increase their market growth which will drive revenues of the company
• In November 2020, Cambrex Corporation had announced that the company will expand their API manufacturing capacity to meet the increasing demand from the consumer side. The company has invested USD 50.00 million to enhance their manufacturing capacity. The increase in API manufacturing will directly increase the production and requirement of intermediates which means that the company has to increase the manufacturing of both API and their intermediates. This expansion has helped the company to enhance their production in both the fields that is APIs and their intermediates which will increase the API intermediates market growth

Europe API Intermediates Market Scope

The Europe API intermediates market is segmented on the basis of type, product, therapeutic type, customers, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Veterinary Drug Intermediates Pharmaceutical
• Bulk Drug Intermediates

Product

• Bromo Compound
• O-Benzyl Salbutamol
• Hemisulfate, Oxirane
• Bisoprolol Base
• Chiral PCBHP
• Pheniramine Base
• Chlorpheniramine Base
• Brompheniramine Base
• Mepyramine/Pyrilamine Base
• 6-Amino-1,3-Dimethyl Uracil
• Theofylline
• Acefylline
• Xanthine
• Nitriles
• Others

Therapeutic Type

• Autoimmune Diseases
• Oncology
• Metabolic Diseases
• Ophthalmology
• Cardiovascular Diseases
• Infectious Diseases
• Neurology
• Respiratory Disorders
• Dermatology
• Urology
• Others

Customers

• Direct Users/Pharma Companies
• Traders/Wholesalers/Distributors
• Associations/Govt. Institutions/PVT Institutions

End User

• API Manufacturer
• Finished Product Manufacturer)

Distribution Channel

• Direct Tender
• Retail Sales
• Others

Europe API Intermediates Market Analysis/Insights

Europe API intermediates market is analyzed, and market size insights and trends are provided by type, product, therapeutic type, customers, end user, and distribution channel as referenced above.

The countries covered in the Europe API intermediates market   report are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe.

Germany dominates the Europe API intermediates market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period 2023-2030. This is due to rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, favorable health remuneration policies, rise in chronic wounds, and a growing elderly population will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Europe API intermediates market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Europe API intermediates market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Europe API intermediates market. The data is available for historic period 2015-2020

Competitive Landscape and Europe API Intermediates Market Share Analysis

The Europe API intermediates market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Europe API intermediates market.

Some of the major players operating in the Europe API intermediates market are:

• HIKAL Ltd.(India)
• Cambrex Corporation (U.S.)
• Ganesh-Group (India)
• AlzChem Group AG (Germany)
• Vasudha Pharma (India)
• Anyang General Chemical Co.,Ltd. (South Korea)
• Sarex (India)
• Sandoo Pharmaceuticals and Chemicals Co., Ltd.(China)
• Atul Ltd (India)
• Sandoz International GmbH (Germany)
• Aceto (U.S.)
• Supriya Lifescience Ltd. (India)
• Vertellus (U.S.)
• Dishman Carbogen Amcis Ltd (India)
• Sanofi (France)
• Divi's Laboratories Limited (India)
• AARTI INDUSTRIES LIMITED (India)
• Aurobindo Pharma (India)
• BASF SE (Germany)